Early recognition of renal toxicity of high-dose methotrexate therapy: A case report

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 12, 2008, Pages 950-952

  Nowicki, Theodore Scott ^a   Bjornard, Kari ^a   Kudlowitz, David ^a   Sandoval, Claudio ^a   Jayabose, Somasundaram ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Carboxypeptidase G; HDMTX; High dose methotrexate; Leucovorin; Osteosarcoma; Renal toxicity

Indexed keywords

CARBOXYPEPTIDASE G2; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; FUROSEMIDE; IFOSFAMIDE; INSULIN; METHOTREXATE; PALIFERMIN; ANTINEOPLASTIC ANTIMETABOLITE; GAMMA GLUTAMYL HYDROLASE;

ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHILD; CLINICAL FEATURE; CYTOPENIA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; HEMODIALYSIS; HEMOPERFUSION; HUMAN; HYPERKALEMIA; HYPOXIA; KIDNEY FAILURE; KIDNEY FUNCTION; LEG AMPUTATION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OSTEOSARCOMA; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; ACUTE KIDNEY FAILURE; BONE TUMOR; CHEMICALLY INDUCED DISORDER; DRUG MONITORING;

ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; CHILD; DRUG MONITORING; GAMMA-GLUTAMYL HYDROLASE; HUMANS; KIDNEY FAILURE, ACUTE; LEUCOVORIN; MALE; METHOTREXATE; OSTEOSARCOMA;

EID: 59149105107     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318182e73e     Document Type: Article

References (10)

1. Esteve M-A, Devictor-Pierre B, Galy G, et al. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypepti-dase G2 rescue and MTX continuation. Eur J Clin Pharmacol. 2007;63:39-42.
2. Hempel L, Misselwitz J, Fleck C, et al. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol. 2003;40:348-354.
3. Widemann BC, Balis FM, Kemph-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004;100:2222-2232.
4. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694-703.
5. Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999;17:1589-1594.
6. Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2 thymidine and leucovorin rescue in cancer patients with metho-trexate induced renal dysfunction. J Clin Oncol. 1997;15:2125-2134.
7. Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005;92:480-487.
8. Saland JM, Leavey PJ, Bash RO, et al. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol. 2002;17:825-829.
9. Frappaz D, Bouffet E, Cochat P, et al. Hemoperfusion on charcoal and hemodialysis in acute poisoning caused by methotrexate. Presse Med. 1988;17:1209-1213.
10. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol. 2002;50:373-382.